



EXTRACTABLES & LEACHABLES FOR SVP-INJECTABLES

PDA TRAINING COURSE EXTRACTABLES – LEACHABLES BASEL 27 – 28 FEBRUARY 2020

Dr. Piet Christiaens







1. Typical Materials of Construction (MoC's) for SVP C/C

- Rubbers 101
- Glass & Glass related issues for E/L
- COP/COC


2. Container Closure Systems for SVP's

- Vials
- Prefilled syringes
- Cartridges

3. Rubber oligomers – safety concern



RECAP: REGULATORY: US




Revision of "Table 1" in USP <1664>, Originally Included into the FDA Guidance for Industry (1999): "Container/Closure systems for Packaging Human Drugs and Biologics"



REGULATORY: US





Remark:

- the "Medium" <u>Likelihood of Packaging DP Interaction</u> for Liquid SVP's is mainly based upon the observation that most Parenteral DP are Aqueous Based. For Nonaqueous based drug products: more caution is needed!
- 2. The "Low" <u>Likelihood of Packaging DP Interaction</u> for LYO SVP's is mainly based upon the observation that:
 - 1. the *interactio*n between a solid (Lyo cake) a material (eg rubber) *is limited*
 - 2. AND, there is *limited direct contact* between Lyo cake and Rubber closure

However the Mechanism of interaction for a LYO Cake and its MoC may not need always a direct contact.

BE CAREFUL when "rationalizing" a LYO application as being Non Critical!!!





1. Typical Materials of Construction for SVP Container/Closure Systems





Elastomeric closures Rubber 101

Supported by Datwyler

A

Parenteral Drug Association






Parenteral Drug Association

Basic composition			
e.g. Elastomer type	Physical/Chemical e.g.	Product performance attributes	
Additives Filler	E&L profile Hardness Compression set Tensile strength	e.g. Drug compatibility Container Closure Integrity Gamma/Steam resistance	Product application
		Fragmentation Gliding curve	

What is rubber?

- An **elastic** material
- A compounded material
- Basis of a rubber \rightarrow polymer \rightarrow elastomer
- Elasticity via crosslinking (curing, vulcanising) the elastomer
- Additional ingredients to "tune" the rubber





Compounded material of:

1. Elastomer

2. Filler



- 4. Pigment
- 5. Other ingredients




Connecting People, Science and Regulation®



Cleanest curing system Lowest permeability $-\begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_2 - C \\ I \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_3 \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_3 \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_3 \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_3 \\ CH_3 \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_3 \\ CH_3 \\ CH_3 \\ CH_3 \end{pmatrix} = \begin{pmatrix} CH_3 \\ I \\ CH_3 \\$ High resistance to ageing

arenteral Drug Associatio

Regular **butyl** still on the market, and also newer types like **BIMS** (Brominated isobutylene para-methylstyrene)



MoC's FOR SVP-INJECTABLES - RUBBERS

X =Cl or Br

1. Elastomers

11

Natural rubber: latex allergy discussions Historically the oldest elastomer type

Need complex curing systems


Natural rubber / Polyisoprene

Good elastic properties

Polyisoprene (synthetic) replaces Natural rubber

MoC's FOR SVP-INJECTABLES - RUBBERS

1. Elastomers



Natural rubbe

Typically not used for parenteral applications **EPDM** rubber

For niche applications

MoC's FOR SVP-INJECTABLES - RUBBERS





trile rubber $(-\overset{H_2}{c}$

Silicone rubber

High permeability







- Fillers give mechanical strength (stiffness) to a rubber
- Attributes **physical properties** to a rubber compound
 - More filler = Harder compound
 - → Better for **gliding** profile plungers
 - → Worse for stopper piercing (coring!)
- Inorganic fillers ('white compounds')
 - Aluminum silicate (clay)
 - Magnesium silicate (talc)
 - Silicate
 - [Calcium carbonate]
- Carbon black ('black compounds')
 - Undesired for cleanliness reasons
 - May be associated with PNA's



PDA[®] MoC's FOR SVP-INJECTABLES - RUBBERS



3. Cure systems

• Cure system:

- Crosslinking agent
- Activator: gives the onset of vulcanization
- Accelerator: speeds up the vulcanization
 - Easily extractable organic molecules such as thiurams, sulfonamides, thiazoles, ...

Modern cure systems


- Aim at giving little extractables

Historic cure systems


- Use easily extractable organic accelerators



Rubber Curing / Vulcanization:



Rubber crosslinking requires S-Donors, activators, accelerators Activator: ZnO / Stearic acid



Note: the Polymerization Starts with a Isobutene Unit (present in high excess!!)

isoprenyl unit

(minor)

isobutyl unit (major)


isoprene propagation

o 98 – 99 mol% is isobutylene

○ 1 – 2 mol% is isoprene




Bromination of a Butyl Elastomer (BIIR)



more reactive in vulcanization/cross linking



Vultac Curing of (Halobutyl) Elastomers



Amyl Disulfide Polymer

Phenol Sulfide Crosslink


Bromide: good leaving group!

Bond Energy C-H 413 J/mol ⇔ C-Br 209 J/mol


Explains Br⁻ release from bromobutyl rubbers




Rubber Curing - Accelerators:



Cyclohexyl benzothiazole sulfenamide




Tetramethylthiuram disulfide(TMTD)




Zinc dimethyldithiocarbamate

Mercaptobenzothiazole disulfide




Diphenyl guanidine



Zinc dibutylphosphorodithiate



ZnO as Cross-Linking Compound in Halobutyl-Rubbers:



PDA Parenteral Drug Association 4. Pigments

Inorganic pigments

- Titanium dioxide
- Traces of carbon black
- Oxides of iron

Organic pigments

- Avoided in modern compounds

PDA[®] MoC's FOR SVP-INJECTABLES - RUBBERS



5. Other ingredients

Halobutyl polymer stabilizers

(to prevent dehydrohalogenation during processing)

- Calcium stearate
- Epoxydized soybean oil

Anti-oxidants

- Already present in halobutyl elastomer
- Hindered phenol type anti-oxidants
- Additionally added to improve environmental stability (ageing)

Plasticizer, Waxes, Oil

(introduce softness, anti-"coring")

- High polymeric weight plasticizers, Paraffinic oil
- To tune a formulation (e.g. reduce coring)
- Processing aids



Smart selection of ingredients can tune a rubber compound

- E.g. recipe based on <u>hydrophobic ingredients</u> will show better E-profile with aqueous drugs
- E.g. blend of <u>halobutyl</u> and <u>SBR</u> can <u>tune</u> the permeability
- E.g. MgO replaces ZnO to avoid Zn-ion extraction
- E.g. low water absorption compounds for lyo applications



But in general too many ingredients should be avoided: negative impact on E-profile

→ "what you don't put in, can't come out"



THE COMPOSITION OF RUBBERS CAN BE VERY COMPLEX!!

RUBBER EXTRACTABLES: SUM OF


- 1. **INITIAL INGREDIENTS** OF THE RUBBER FORMULATION
- 2. **IMPURITIES** OF THESE INGREDIENTS

(e.g. Residual Solvents, **Oligomers in Elastomer**, Halides in Halobutyl Rubber...)


3. **REACTION/DEGRADATION PRODUCTS** DURING RUBBER PRODUCTION














Number of Leachables from rubbers in PFS is determined by:

- The Type of Rubber Formulation
- The Number of Ingredients in the Rubber
- **Type** of Ingredients (type of vulcanisation, type of AO, stabilizer....)
- Coated/Non-coated rubbers
- The composition of the Medicinal Product (MP)
- The **type of contact** between the rubber and the MP (*e.g. exposed surface area*)
- The Storage Temperature
- The **Storage Time** (Expiration Date)

PDA[®] MoC's FOR SVP-INJECTABLES - RUBBERS




Difference in Extractable Results for an **OLD** vs **NEW** rubber (*IPA Extract; GC/MS analysis*)






COATED RUBBERS

Coated closures: significant <u>improvement in E&L terms</u> Key attribute: <u>barrier effect</u> from the fluoropolymer! Simplified extractables profile Improved compatibility with drugs/excipients




Film coating technology

Spray coating technology





Difference in Extractable Results for a **Coated vs Uncoated rubber**, for the same rubber grade (*IPA Extract; GC/MS analysis*)







Glass

&

Glass Related Issues


Vials, Prefilled Syringes, Cartridges



Glass as Barrel Material

TUNGSTEN RESIDUES

- <u>Tungsten pin</u> used in the production of glass pre-filled syringes to open the syringe hub (cavity where staked needle is glued in)
- <u>Tungsten Oxide Residues</u> are known to cause <u>protein degradation</u> (protein oxidation causing aggregation)





Glass as Barrel Material

GLUE RESIDUES

- Glue is used to glue in the staked needle into the PFS-system
- > <u>Prolonged contact</u> with a drug product may release glue components
- Target compounds may depend upon the glue used (e.g. Loctite 3345, Loctite 3081, or other grades)

PDA MoC's FOR SVP-INJECTABLES - GLASS

Product name: Product type:

Parenteral Drug Association

Loctite 3345 Ultraviolet adhesive

Company address: Henkel Corporation One Henkel Way Rocky Hill, Connecticut 06067 IDH number:256930Item number:33417Region:United StatesContact information:Telephone:860.571.5100MEDICAL EMERGENCY Phone:Poison Control Center1-877-671-4608 (toll free) or1-303-592-1711TRANSPORT EMERGENCY Phone:CHEMTREC1-800-424-9300 (toll free) or1-703-527-3887Internet:www.henkelna.com

3. COMPOSITION / INFORMATION ON INGREDIENTS

Glass as Barrel Material – Related Compound

1. PRODUCT AND COMPANY IDENTIFICATION


Hazardous components	CAS NUMBER	%	
Polyurethane Methacrylate Resin	Proprietary	30 - 60	
Tetrahydrofurfuryl methacrylate	2455-24-5	10 - 30	
Hydroxyalkyl methacrylate	27813-02-1	10 - 30	
Acrylic acid	79-10-7	5 - 10	
High boiling methacrylate	7534-94-3	5 - 10	
Propylidynetrimethyl trimethacrylate	3290-92-4	1 - 5	
Gamma-glycidoxypropyl trimethoxysilane	2530-83-8	1 - 5	





Glass as Barrel Material – Related Compounds


EXTRACTABLES RELATED TO GLASS BARRELS: GLUE RESIDUES


Base Polymer












Camphene


Acrylate

Methacrylate



Isoborneol

UV curing / activation







Irgacure 184

Benzaldehyde


Cyclohexanone



Glass as Barrel Material – Related Compounds

EXTRACTABLES RELATED TO GLASS BARRELS: GLUE RESIDUES

The key indicator compound TMPTMA



Trimethylolpropane trimethacrylate



Glass as Barrel Material – Related Compounds

SILICONE OIL RESIDUES

- Glass surfaces are siliconized a.o. to reduce potential interactions with aqueous contact solutions
- Hydrophobic surface / reduced wettability
- Reduced alkali release
- Silicone oil remainders <u>become leachables</u>



Barrel Materials

Polypropylene (PP)

Cyclic Olefin (Co-)Polymer COC/COP

Glass


PDA[®] MoC's FOR SVP-INJECTABLES – COP/COC

COP: <u>Cyclic O</u>lefin <u>P</u>olymers COC: <u>Cyclic O</u>lefin <u>C</u>opolymers

- Relatively Clean Materials
- High Tg, rigid materials

interal Drug Associati

- However, low gas barrier (O₂) properties
- Risk for diffusion: potential (regulatory) risk for label migration



PDA MOC'S FOR SVP-INJECTABLES – COP/COC



CRITICAL PARTS OF A POLYMER SYRINGE WRT E/L

PRIMARY PACKAGING (Direct Contact between DP and Material):

- The Barrel: COC, COP, PP
- The Piston: Rubber
- The Tip Cap: Rubber Same Concern as for Glass PFS
- The Needle

SECONDARY PACKAGING (No Direct Contact between DP and Material):

- The Needle Shield (should it be considered as primary or secondary?): Rubber
- The Label: Adhesive, Ink, other Label Components
- In some Cases: The Lacker
- In some Cases: The Packaging of the Syringe (Overwrap, Tubs,...)

Specific for

Polymer PFS!


PDA[®] MoC's FOR SVP-INJECTABLES – COP/COC

TYPICAL COMPOSITION OF COMMERCIAL POLYMERS,

e.g. For Barrel Manufacture

Parenteral Drug Associatio

- o Additives (BHT, Irganox 1010, Stearates, Pigments, Clarifyers...)
- Residues (Monomers, Solvent Residues, Processing Residues..)
- Oligomers (Mainly for PP)
- Potential Degradation Compounds from Polymers
 Organic Acids, Aldehydes, Ketones, Alcohols, Chain Scission Fragments...
- $_{\odot}$ Degradation Compounds from Polymer Additives





SECONDARY PACKAGING

≻Label

- > Adhesive
- ➤ Paper
- ≻ Ink
- Varnish


Typical extractable compounds:

Curing agents (e.g. Benzophenone, Irgacure 184,...) Solvent residues (e.g.Toluene, acetone) Adhesive residues (e.g. Acrylates) Paper residues (e.g. (dehydro)abietic acids, abietates)

PDA MoC's FOR SVP-INJECTABLES – COP/COC

Parenteral Drug Association

Example GC/MS Chromatogram of a Label Extract (IPA)



PDA MOC'S FOR SVP-INJECTABLES – COP/COC

A

SECONDARY PACKAGING




> Overwrap/Overpouch/Blister

(to compensate for potential lower barrier properties of the Polymer)

- Multilayer System
- Aluminum as barrier layer
- Tie-layers to keep the different layers together

Typical extractable compounds:

Bislactone Compounds from Tie-layer Compounds from Tie-layer Compounds from Tie-layer Compounds largely on selected materials of the multilayer!!)




CH₃

PDA MoC's FOR SVP-INJECTABLES – COP/COC


SECONDARY PACKAGING

Parenteral Drug Associatio

- Tubs for Nested Syringes (eg Tyvek)
- > Carton / Paper (may also from label):



Example Structures of abietic acids / abietates (& Vanillin)







2. Container/Closure Systems for SVP's: Information Relevant to the Design of an E&L Study



1.Vials:



VIALS for Liquid Drug Products or Reconstitution Solution



- If it is a **GLASS VIAL with RUBBER CLOSURE:** Sources of Impurities, coming from packaging:
 - Glass: Metals (may not be necessary to be studied in EXT Study, if glass composition is available, direct assessment in LEA study)

Rubber Closure:

- ✓ Typically, higher migration when solution is in contact (inverted)
- \checkmark Migration will be determined by:
 - Solubility of leachables in Drug Product Solution
 - Potential Diffusion of Compounds through rubber, into solution
 - Temperature
- ✓ VOC, SVOC and NVOC & some metals may cause a Safety Issue
- ✓ VOC, SVOC, NVOC, Silicone Oil and some Metals may also be Reactive e.g. with reconstituted DP: also potential Performance & Quality Issue!
- ✓ Also, lons may need to be "checked off"...

LYO-CAKE VIAL

- Sources of impurities, coming from packaging
 - Glass: Metals (may not be necessary to be studied in EXT Study, if glass composition is available, direct assessment in LEA study)
 - > Rubber Closure:
 - ✓ **No Direct Contact** between DP and Closure (upright)
 - ✓ HOWEVER: Release of Volatile (VOC) and Semi-Volatile (SVOC) Compounds from the Rubber Closure vial desorption and subsequent adsorbtion of compounds onto Lyo-Cake!
 - Lyo-cake acts as adsorbent for VOC and SVOC compounds! Released Compounds are concentrated over time onto the Lyo Cake
 - Regardless if vial is in upright or inverted position (contact / no contact with DP)
 - VOC and SVOC may also be Reactive with DP: also potential Performance & Quality Issue!
 - ✓ Also NVOC, Metals and Ions need to be "checked off", because of short term contact with Reconstituted DP.







2. Pre-Filled Syringe:




PRE-FILLED SYRINGE: COMPOSING PARTS











BARREL – Glass, COC/COP, PP, Silicone Oil, ...



NEEDLE – Metals, Tungsten (W), Needle Glue, ...



RUBBER SEALINGS (Plunger Tip, Tip Cap, Disks) -Rubber, Silicone, ...



SECONDARY (Needle Shield, Label, Stem, ...) – Rubber, Label Adhesive, ...

Pre-Filled Syringes




- BARREL: Metals (may not be necessary to be studied in EXT Study, if glass composition is available, direct assessment in LEA study) Silicone Oil residues may cause protein aggregation
- Rubber Plunger (very similar to rubber stopper for vial):
 - \checkmark Typically, higher migration when solution is in contact
 - ✓ Migration will be determined by:
 - Solubility of leachables in Drug Product Solution
 - Potential Diffusion of Compounds through rubber, into solution
 - Temperature
 - \checkmark VOC, SVOC and NVOC may cause a safety issue
 - ✓ VOC, SVOC, NVOC, Silicone Oil and some Metals may also be **Reactive** with reconstituted DP: also potential Performance & Quality Issue!
 - ✓ Also, lons may need to be "checked off"...
 - ✓ Coated versus Non-Coated plungers





- GLUE for staked needle: Glue residues may for protein denaturation
- **TUNGSTEN Residues**: May cause protein aggregation
- NEEDLE SHIELD:
 - No Direct Contact between DP and Needle Shield
 - **HOWEVER:** Release of Volatile (VOC) and Semi-Volatile (SVOC) Compounds from the Needle shield into the content of the PFS is possible!
 - VOC and SVOC may also be Reactive with DP: also potential Performance & Quality Issue!
 - Typically No NVOC, Metals and lons investigation is necessary for a Needle Shield.








3. Cartridges









Sealing Disk:

- ✓ Typically, a sealing disk is a two-layered system
- The inner layer has product contact (primary contact), should be the focus of the investigation
- "One Sided" extraction mimics the product contact, avoids contribution of the outer layer
- Complete Extraction of the 2 layered sealing disk can be considered as "Worst Case"
- ✓ Both approaches can be taken and have found regulatory acceptance





BARREL: Metals (may not be necessary to be studied in EXT Study, if glass composition is available, direct assessment in LEA study) Silicone Oil residues may cause protein aggregation

Cartridge Plunger (same as for PFS!):

- ✓ Typically, higher migration when solution is in contact (inverted)
- ✓ Migration will be determined by:
 - Solubility of leachables in Reconstitution Solution (typically inorganic aqueous solution (typically low solubility for most non-polar organic compounds)
 - Potential Diffusion of Compounds through rubber, into solution
 - Temperature
- ✓ VOC, SVOC and NVOC may cause a safety issue
- ✓ VOC, SVOC, NVOC, Silicone Oil and some Metals may also be **Reactive** with reconstituted DP: also potential Performance & Quality Issue!
- ✓ Also, lons may need to be "checked off"...






RUBBER OLIGOMERS: MAY NEED MORE ATTENTION



$C_{13}H_{24}$ and $C_{21}H_{40}$ Oligomers

- Considered as
 - Cyclic aliphatic hydrocarbon compounds
 - One double bond
- No experimental data / Literature data is known about toxicity of these compounds
- Structure Activity Relationship Assessment (SAR): compound of low tox. risk.



PDA 3. RUBBER OLIGOMERS

Halogenated Rubber Oligomers – Compounds of high concern

 $C_{13}H_{23}Br/C_{13}H_{23}Cl and C_{21}H_{39}Br/C_{21}H_{39}Cl Oligomers$

Considered as

arenteral Drug Associat

• HALOGENATED Cyclic Aliphatic Hydrobarbon compounds (Allyl Halide)

H₂C

- Alkylating Agents
- One double bond
- Structure Activity Relationship (SAR) Assessment:

CARCINOGENICITY IN HUMANS IS PLAUSIBLE

- As no experimental data / Literature data is known about the toxicity of these compounds, a lot of Pharma companies:
 - <u>Rely on the result of a SAR assessment</u> to perform a tox evaluation
 - <u>Conclude</u> that these compounds are of <u>High Concern</u>

PDA 3. RUBBER OLIGOMERS



For potential Mutagenic/Carcinogenic compounds:

SCT: 0.15 µg/day (PQRI OINDP)

SCT: 1.5 µg/day (PQRI-PODP; ICH guideline on Genotoxic Impurities)

The low SCT/TTC levels for the Halogenated Oligomers mean:

- Low associated AET levels
- > High level of method optimization to obtain these levels (certainly with LVP)
- ➢ e.g. SIM mode for GC/MS
- Can only be performed with appropriate analytical standards with known purity
 - Method Selectivity
 - Accuracy
 - Sensitivity
 - Precision
 - ...





Cresol containing drug products, Bromocresol may be formed in the presence of Bromobutyl Stoppers (Mechanism is unknown)





Formation of C₁₃H₂₃OH out of C₁₃H₂₃Br in Lyo Products







REGULATORY: US

Guidance ft Interactions between therapeutic protein products and the container closure may negatively affect product quality and immunogenicity. These interactions are more likely with prefilled syringes of therapeutic protein products. These syringes are composed of multiple surfaces and materials that interact with the therapeutic protein product over a prolonged time period and thus have the potential to alter product quality and immunogenicity. The following are other container closure considerations pertinent to immunogenicity:

Immunogenicity Considerations pertine Therapeutic Protein Products

> U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER)

> > August 2014 Clinical/Medical

FDA Guidance for Industry, 2014


"... Interactions are more likely with prefilled syringes of therapeutic protein products..."

"... Materials that interact with the therapeutic protein product over a prolonged time and thus have the potential to alter product quality and immunogenicity..."



Observed Reactivity of $C_{13}H_{23}Br$ and $C_{21}H_{39}Br$

(as alkyating agents) with peptides, proteins, and nucleic acids





ANY QUESTIONS?